Document is current
Any future updates will be listed below
-
Authors
Hibi, Toshifumi https://orcid.org/0000-0002-6256-1204
Kobayashi, Taku https://orcid.org/0000-0002-2073-4234
Tanaka, Masaru https://orcid.org/0009-0008-7302-8692
Osaga, Satoshi https://orcid.org/0000-0003-4459-2469
Potts Bleakman, Alison J. https://orcid.org/0000-0001-8373-6299
Hunter Gibble, Theresa https://orcid.org/0000-0001-8412-9175
Nedeljkovic Protic, Marijana https://orcid.org/0009-0009-2172-8598
Redondo, Isabel https://orcid.org/0009-0008-1549-680X
Matsuo, Koji https://orcid.org/0000-0002-4862-8927
Hisamatsu, Tadakazu https://orcid.org/0000-0002-1178-3536
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 21 July 2024
Accepted: 22 November 2024
First Online: 28 February 2025
Declarations
:
: Toshifumi Hibi received consultancy fees/grants/research support and/or was a speaker for AbbVie GK, ActivAid, Alfresa Pharma Corporation, Bristol Myers Squibb, Celltrion, EA Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, JMDC Inc., Kyorin, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Nippon Kayaku Co., Pfizer, Sandoz, Takeda Pharmaceutical, Zeria Pharmaceutical, and MIYARISAN Pharmaceutical. Taku Kobayashi served as an advisory board member, consultant or speaker for AbbVie, Activaid, Alfresa Pharma, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Gilead Sciences, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Takeda, and Zeria Pharmaceutical. Masaru Tanaka and Satoshi Osaga are full time employees of Eli Lilly Japan K.K. and minor stockholders of Eli Lilly and Company. Koji Matsuo was a full-time employee of Eli Lilly Japan K.K at the time this work was completed and is now affiliated with Naramachi Internal Medicine Airi Ladies’ Clinic. Alison Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, and Isabel Redondo are full time employees of Eli Lilly and Company. Alison Potts Bleakman is a stockholder of Eli Lilly and Company. Tadakazu Hisamatsu received grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., Boston Scientific Corporation, and Kissei Pharmaceutical Co. Ltd; consulting fees from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co. Ltd., Eli Lilly and Company, Gilead Sciences, and Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA Pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., and Kissei Pharmaceutical Co. Ltd.
: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Pharmacoepidemiology Practice guidelines, and all local laws and regulations. All participants provided informed consent prior to participating in the study. The protocol and data collection materials were approved by the Western Institutional Review Board.
